Carisma Therapeutics Inc SESN

Primary Symbol: CARM

Healthcare Biotechnology

Carisma Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on utilizing its proprietary macrophage and monocyte cell engineering platform to develop transformative immunotherapies to treat cancer and other serious diseases. It is developing a pipeline of product candidates, with an initial focus on advancing multiple ex vivo autologous and in vivo CAR-M therapies for the treatment of solid tumors. Its first product candidate, CT-0508, is an ex vivo gene-modified autologous chimeric antigen receptor-monocyte (CAR-Monocyte) cellular therapy intended to treat solid tumors that overexpress human epidermal growth factor receptor 2 (HER2). Its second product candidate, CT-0525, is an ex vivo gene-modified autologous chimeric antigen receptor-macrophage (CAR-Macrophage) cellular therapy intended to treat solid tumors that overexpress HER2. CT-1119 is a mesothelin-targeted CAR-Monocyte that is designed to treat patients with advanced mesothelin-positive solid tumors.

NDAQ:CARM - Post by User

Carisma Therapeutics Inc

<< Previous

Bullboard Posts

Next >>

Post by floatinketuckyon Jan 24, 2022 6:48am

215 Views

Post# 34351315

sesn flying flamming turd

To catch is risk of splatter and burn. The market know for sure. Just look to the chart.
More pain cometh.

This song is Break it to me gently. But it was not gentle at all. The market knew quick. Play with a dead cat and get scratched.

Down down down.. The market know SESN is not the FDA Darlin.

I'm as bearish as the chart and facts.

As bearish as the FDA guidlines for them...

<< Previous

Bullboard Posts

Next >>

Retail giant Walmart Canada celebrates 30 years of business